Fig. 2

RhoA-MKL-1 and JAK3-STAT5b signaling stabilizes the activated Treg development and function. a Percentage of proliferated cells in 2:1 Treg: CD4⁺T cells and treated AG490 for 48 h (n = 6, SEM, t test). Data are representative of three experiments; b Percentage of proliferated cells in 2:1 Treg: CD4⁺T cells and treated Y27632 for 48 h (n = 6, SEM, t test). Data are representative of three experiments; c Percentage of proliferated cells in 2:1 Treg: CD4⁺T cells and treated AG490 or Y27632 for 48 h (n = 6, SEM, t test). Data are representative of three experiments; d and e Proliferation stimulated with anti-CD3/CD28 beads for 48 h determined by eFluor670 proliferation dye staining in a 2:1 or 10:1 (Foxp3+ Treg: CD4⁺T cells) ratio with or without 50 ng/mL IL-2 for 48 h (n = 6, SEM, t test); f, g and h IL-2 binding by medium and AG490 or Y27632–stimulated Foxp3⁺ Treg in the absence orpresence of CD3/CD28 bead stimulation. (n = 6, SEM, t test)